What is Generate Biomedicines, Inc. Common Stock (GENB) stock price today?

Generate Biomedicines, Inc. Common Stock (GENB) currently trades at $15.30 per share. The stock has a market capitalization of $1.97B and a P/E ratio of —x.

Is GENB stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Generate Biomedicines, Inc. Common Stock has a Smart Value Score of 16/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Generate Biomedicines, Inc. Common Stock's revenue and earnings?

Generate Biomedicines, Inc. Common Stock has trailing twelve-month (TTM) revenue of $31.89M with profit margins of 0.00%. Earnings per share (EPS) is $-2.18.

GENB

Generate Biomedicines, Inc. Common Stock

NASDAQ: GENB · HEALTHCARE · BIOTECHNOLOGY

$15.30

-0.78% today

Updated 2026-05-06

Market cap

$1.97B

P/E ratio

—

P/S ratio

61.62x

EPS (TTM)

$-2.18

Dividend yield

—

52W range

$11 – $16

Volume

0.6M

Market cap

$1.97B

P/E ratio

—

P/S ratio

61.62x

EPS (TTM)

$-2.18

Dividend yield

—

52W range

$11 – $16

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.0

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →197 stocks currently score above 75

Price targets

Analyst target

$23.20

+51.63%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-204.13M

Key financials

Revenue Net Income Free Cash Flow

Metric	2024	2025	TTM
Revenue	$20.46M	$31.89M	$31.89M
Net income	$-173.77M	$-203.15M	$-203.15M
EPS	—	—	$-2.18
Free cash flow	$-121.20M	$-204.13M	$-204.13M
Profit margin	-849.36%	-636.99%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GENB	$1.97B	16	6.0	2.5	5.0	5.0	—	Avoid
LLY	$862.01B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$546.90B	59	4.7	9.0	3.3	6.0	-40.34%	Buy
ABBV	$365.43B	63	4.0	8.0	4.0	5.0	-22.55%	Buy
UNH	$336.72B	54	5.3	5.5	7.3	4.8	+43.12%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+3.99%	Buy

Smart narrative

Generate Biomedicines, Inc. Common Stock trades at $15.30. Our Smart Value Score of 16/100 indicates the stock is weak. TTM revenue stands at $31.89M.

Frequently asked questions

What is Generate Biomedicines, Inc. Common Stock's stock price?

Generate Biomedicines, Inc. Common Stock (GENB) trades at $15.30.

Is Generate Biomedicines, Inc. Common Stock overvalued?

Smart Value Score 16/100 (Grade F, Strong Sell).

What is the price target of Generate Biomedicines, Inc. Common Stock (GENB)?

The analyst target price is $23.20, representing +51.6% upside from the current price of $15.30.

What is Generate Biomedicines, Inc. Common Stock's revenue?

TTM revenue is $31.89M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio61.62x

ROE-81.70%

Beta—

50D MA$12.41

200D MA$12.41

Shares out0.13B

Float0.05B

Short ratio—

Avg volume0.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

GENB vs LLY →GENB vs JNJ →GENB vs ABBV →Stock screener →